Thai buy expands Fuji's production base and hones DKSH's market expansion focus
This article was originally published in Scrip
Japan's Fuji Pharma has agreed to pay around ¥4.2 billion ($53.6 million) to acquire the largest facility in Thailand for the contract manufacture of pharmaceuticals, in a deal that will also relieve current owner DKSH of a non-core asset.
You may also be interested in...
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Diversified Japanese giant to launch tender for Danish transplant drug specialist as it looks to build US operations for health care business. Lundbeck and Novo Nordisk among investors that will see an exit.